TipRanksStock Market NewsADMP NewsAdamis Pharma Updates 1 Key Risk Factor
Market News

Adamis Pharma Updates 1 Key Risk Factor

Specialty biopharmaceutical company Adamis Pharmaceuticals Corp. (ADMP) announced it has submitted a fast-track application for Tempol to the U.S. Food and Drug Administration (FDA), earlier this week.

The drug is being developed for the treatment and prevention of COVID-19 and is currently in a Phase 2/3 clinical trial in patients affected by COVID-19.

Importantly, Tempol has demonstrated antiviral, anti-inflammatory, and antioxidant activity. While there have been recent approvals for oral antiviral drugs, Adamis noted Tempol’s unique mechanism of action and safety profile would offer an unmet medical requirement.

With this development in mind, let us take a look at the changes in Adamis’ key risk factors that investors should know.

Risk Factors

According to the TipRanks Risk Factors tool, Adamis Pharma’s top risk category is Finance & Corporate, contributing 41% (compared to a sector average of 29%) to the total 63 risks identified. In its recent quarterly report, the company has added one key risk factor under the Tech & Innovation risk category.

Adamis noted that developing new pharmaceutical products is a risky activity. There can be no guarantee if R&D efforts or clinical trials would fructify into viable products or satisfy safety standards.

Tracking Insiders

Keeping a tab on insiders stocks can provide timely insights for retail investors. TipRanks data on Insider Activity points that insiders have sold Adamis Pharma shares worth $115.2 thousand in the last three months, indicating a very negative insider confidence signal for the stock based on 4 insider transactions in the last 3 months.

To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Read full Disclaimer & Disclosure

Download the TipRanks mobile app now

Related News:
Tesla Inks First U.S. Nickel Supply Deal with Talon Metals 
Moderna Provides COVID-19 Vaccine Update; Shares Jump 9% 
Intel Jumps 3% on Appointment of New CFO

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More